Table 2.
Cross-reactivity analysis.
Cross Reactivity Studies |
sBCMA Concentration of 70.0 ng/mL |
||
---|---|---|---|
Drug Name | Drug Concentration (% of total solution) | Percent Cross -Reactivity | Percent Recovery |
Daratumumab | 5% | 3% | 103% |
10% | −4% | 96% | |
Isatuximab | 5% | 2% | 101% |
10% | −4% | 97% | |
Talquetamab | 2% | 1% | 101% |
5% | 4% | 105% | |
8% | −1% | 103% | |
10% | 0.4 | 105% | |
Belantamab | 1% | −1875% | 5% |
5% | −2477% | 4% | |
10% | −2168% | 5% | |
AMG 701 | 2% | −474% | 18% |
5% | −923% | 10% | |
8% | −966% | 10% | |
10% | −998% | 10% |